Yervoy Pregnancy Surveillance Study

• Status: Recruiting
• Trial end date: 2024-08-31
• Target enrollment: 0
• Participant gender: Female

Summary

The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Ipilimumab

Criteria

Inclusion Criteria:

• Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment

Exclusion Criteria:

• Women whose ipilimumab exposure is outside the window of pregnancy exposure

• Pregnancies for which there is only paternal exposure to Yervoy

Other protocol defined inclusion/exclusion criteria could apply